YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics

Abstract excerpt

Significance Despite high response rates to treatment with small molecule inhibitors of EGFR tyrosine kinase activity, patients with EGFR -mutant lung adenocarcinomas eventually develop resistance to these drugs. In many cases, the basis of acquired resistance remains unclear. We have used a transposon mutagenesis screen in an EGFR -mutant cell line and clinical genomic sequencing in cases of acquired resistance...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Genomics and Diagnostics
• Share to Lung Cancer Treatments and Mutations
• Share to vaccines and immunoinformatics approaches